bluuebunny/crossref_metadata_2025_split huggingface dataset:
Syntheses and Reactions of Hexavalent Organotellurium Compounds Bearing Five or Six TelluriumCarbon Bonds
Authors: Miyasato Masataka , Sagami Takao , Minoura Mao , Yamamoto Yohsuke , Akiba Kin‐ya 
Published: March 2004

AbstractA variety of hexaorganotellurium compounds, Ar6−n(CH3)nTe [Ar=4‐CF3C6H4, n=0 (1 a), n=1 (3 a), n=2 (trans‐4 a and cis‐4 a), n=3 (mer‐5 a), n=4 (trans‐6 a); Ph, n=0 (1 b), n=1 (3 b), n=2 (trans‐4 b); 4‐CH3C6H4, n=0 (1 c), n=1 (3 c), n=2 (trans‐4 c), n=4 (trans‐6 c); 4‐BrC6H4, n=0 (1 d)] and Ar5(R)Te [Ar=4‐CF3C6H4, R=4‐CH3OC6H4 (8); Ar=4‐CF3C6H4, R=vinyl (9), Ar=Ph, R=vinyl (10), Ar=4‐CF3C6H4, R=PhSCH2 (11), Ar=Ph, R=PhSCH2 (12), Ar=4‐CF3C6H4, R=nBu (13)] and pentaorganotellurium halides, Ar5TeX [Ar=4‐CF3C6H4, X=Cl (2 a‐Cl), X=Br (2 a‐Br); Ar=Ph, X=Cl (2 b‐Cl), X=Br (2 b‐Br); Ar=4‐CH3C6H4, X=Cl (2 c‐Cl), X=Br (2 c‐Br); Ar=4‐BrC6H4, X=Br (2 d‐Br)] and (4‐CF3C6H4)4(CH3)TeX [X=Cl (trans‐7 a‐Cl) and X=Br (trans‐7 a‐Br)] were synthesized by the following methods: 1) one‐pot synthesis of 1 a, 2) the reaction of SO2Cl2 or Br2 with Ar5Te−Li+ generated from TeCl4 or TeBr4 with five equivalents of ArLi, 3) reductive cleavage of Ar6−m(CH3)mTe (m=0 or 2) with KC8 followed by treatment with CH3I, 4) valence expansion reaction from low‐valent tellurium compounds by treatment with KC8 followed by reaction with CH3I, 5) nucleophilic substitution of Ar6−y−z(CH3)zTeXy−z (X=Cl, Br, OTf; z=0, 1; y=1, 2) with organolithium reagents. The scope and limitations and some details for each method are discussed and electrophilic halogenation of the hexaorganotellurium compounds is also described.
Synthesis of C3 Benzo[1,2‐e:3,4‐e′:5,6‐e′′]tribenzo[l]acephenanthrylenes (“Crushed Fullerene” Derivatives) by Intramolecular Palladium‐Catalyzed Arylation
Authors: Gómez‐Lor Berta , González‐Cantalapiedra Esther , Ruiz Marta , de Frutos Óscar , Cárdenas Diego J. , Santos Amelia , Echavarren Antonio M. 
Published: March 2004

AbstractThe C60 polyarenes 4, 5, 18 a, and 18 b have been synthesized from truxene by triple alkylation at C5, C10, and C15 followed by a palladium‐catalyzed intramolecular arylation. The synthesis of “crushed fullerene” C60H30 (2) is the most efficient reported to date and proceeds in 33 % overall yield.
[K36(μ6‐Cl)2 (H2O)11(MeOH)32][SnSe4] [Co4(μ4‐Se)(SnSe4)4] 3: Synthesis and Crystal Structure of a Novel Compound Containing Ternary [Co4(μ4‐Se)(SnSe4)4] 10‐ Anions and a Novel [(μ6‐Cl)2K9]7+ Coordination Aggregate.
Authors: Melullis Maike , Zimmermann Christian , Anson Christopher E. , Dehnen Stefanie 
Published: April 2004

AbstractFor Abstract see ChemInform Abstract in Full Text.
A Facile Diastereoselective Synthesis of Functionalized 1,2,3‐Trisubstituted Benzocyclopentenes Through the Cycloaddition of Bis(phenylsulfonyl)iodonium Ylides to Cyclic Alkenes.
Authors: Adam Waldemar , Gogonas Efstathios P. , Hadjiarapoglou Lazaros P. 
Published: April 2004

AbstractFor Abstract see ChemInform Abstract in Full Text.
Synthesis of Polyfluorophenyl Substituted‐4,5‐dihydropyrazole Derivatives via 1,3‐Dipolar Cycloaddition of Nitrile Imine with Ethyl Acrylate.
Authors: Song Li‐Ping , Zhu Shi‐Zheng 
Published: April 2004

AbstractFor Abstract see ChemInform Abstract in Full Text.
The First Nonthiolic, Odorless 1,3‐Propanedithiol Equivalent and Its Application in Thioacetalization.
Authors: Liu Qun , Che Guangbo , Yu Haifeng , Liu Yingchun , Zhang Jingping , Zhang Qian , Dong Dewen 
Published: April 2004

AbstractFor Abstract see ChemInform Abstract in Full Text.
Synthesis, Structural Characterization and in vitro Antitumor Activity of 4‐Dimethylaminopyridinium (6‐Chloro‐1,1‐dioxo‐1,4,2‐benzodithiazin‐3‐yl)methanides.
Authors: Brzozowski Zdzislaw , Saczewski Franciszek , Gdaniec Maria 
Published: April 2004

AbstractFor Abstract see ChemInform Abstract in Full Text.
Reaction of 5‐Halo‐1,2,3‐thiadiazoles with Aliphatic Diamines. Synthesis and Intramolecular Cyclization of Bis(1,2,3‐triazolyl‐1,2,3‐thiadiazolyl)sulfides.
Authors: Volkova Natalya N. , Tarasov Evgeniy V. , Kodess Mikhail I. , Van Meervelt Luc , Dehaen Wim , Bakulev Vasiliy A. 
Published: April 2004

AbstractFor Abstract see ChemInform Abstract in Full Text.
Synthesis and anti‐HBV Activity of Thiouracils Linked via S and N‐1 to the 5‐Position of Methyl β‐D‐Ribofuranoside.
Authors: Abdel‐Rahman Adel A.‐H. , Abdel‐Megied Ahmed E.‐S. , Goda Adel E.‐S. , Zeid Ibrahim F. , El Ashry El Sayed H. 
Published: April 2004

AbstractFor Abstract see ChemInform Abstract in Full Text.
Antibiotics from Gliding Bacteria. Part 94. Cyrmenins, New β‐Methoxyacrylate Inhibitors of the Electron Transport. Production, Isolation, Physico‐Chemical and Biological Properties.
Authors: Sasse Florenz , Leibold Thomas , Kunze Brigitte , Hoefle Gerhard , Reichenbach Hans 
Published: April 2004

AbstractFor Abstract see ChemInform Abstract in Full Text.
Lanopylins A1, B1, A2 and B2, Novel Lanosterol Synthase Inhibitors from Streptomyces sp. K99‐5041.
Authors: Sakano Yuichi , Shibuya Masaaki , Matsumoto Atsuko , Takahashi Yoko , Tomoda Hiroshi , Omura Satoshi , Ebizuka Yutaka 
Published: April 2004

AbstractFor Abstract see ChemInform Abstract in Full Text.
SMTP‐4D, ‐5D, ‐6D, ‐7D and ‐8D, a New Series of the Non‐Lysine‐Analogue Plasminogen Modulators with a D‐Amino Acid Moiety.
Authors: Hu Weimin , Kitano Yoshikazu , Hasumi Keiji 
Published: April 2004

AbstractFor Abstract see ChemInform Abstract in Full Text.
Polyoxolenes May Provide a Tool for Designing Paramagnetic Molecules with Predetermined Spin Topologies
Authors: Bencini Alessandro , Caneschi Andrea , Dei Andrea , Gatteschi Dante , Sangregorio Claudio , Shultz David , Sorace Lorenzo , Vaz Maria G. F. 
Published: April 2004

AbstractFor Abstract see ChemInform Abstract in Full Text.
Palladium‐Catalyzed Cross‐Coupling Reactions and Electrocyclizations—Efficient Combinations for New Cascade Reactions.
Authors: de Meijere Armin , Schelper Michael , Knoke Mario , Yucel Baris , Suennemann Hans Wolf , Scheurich Rene Peter , Arve Lars 
Published: April 2004

AbstractFor Abstract see ChemInform Abstract in Full Text.
Recall and detection rates in screening mammography
Authors: Gur David , Sumkin Jules H. , Hardesty Lara A. , Clearfield Ronald J. , Cohen Cathy S. , Ganott Marie A. , Hakim Christiane M. , Harris Kathleen M. , Poller William R. , Shah Ratan , Wallace Luisa P. , Rockette Howard E. 
Published: March 2004

AbstractBACKGROUNDThe authors investigated the correlation between recall and detection rates in a group of 10 radiologists who had read a high volume of screening mammograms in an academic institution.METHODSPractice‐related and outcome‐related databases of verified cases were used to compute recall rates and tumor detection rates for a group of 10 Mammography Quality Standard Act (MQSA)‐certified radiologists who interpreted a total of 98,668 screening mammograms during the years 2000, 2001, and 2002. The relation between recall and detection rates for these individuals was investigated using parametric Pearson (r) and nonparametric Spearman (rho) correlation coefficients. The effect of the volume of mammograms interpreted by individual radiologists was assessed using partial correlations controlling for total reading volumes.RESULTSA wide variability of recall rates (range, 7.7–17.2%) and detection rates (range, 2.6–5.4 per 1000 mammograms) was observed in the current study. A statistically significant correlation (P < 0.05) between recall and detection rates was observed in this group of 10 experienced radiologists. The results remained significant (P < 0.05) after accounting for the volume of mammograms interpreted by each radiologist.CONCLUSIONSOptimal performance in screening mammography should be evaluated quantitatively. The general pressure to reduce recall rates through “practice guidelines” to below a fixed level for all radiologists should be assessed carefully. Cancer 2004. © 2004 American Cancer Society.
Predictors of prostate‐specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy
Authors: Freedland Stephen J. , Aronson William J. , Presti Joseph C. , Amling Christopher L. , Terris Martha K. , Trock Bruce , Kane Christopher J. 
Published: March 2004

AbstractBACKGROUNDSeminal vesicle (SV) invasion at the time of radical prostatectomy (RP) generally is considered to be indicative of poor outcome. The authors examined whether there was a subset of men with SV invasion who had long‐term prostate‐specific antigen (PSA) progression–free survival.METHODSData were examined from 1687 men who underwent RP between 1988 and 2002 at 5 equal‐access medical centers. Patients were grouped based on the presence or absence of SV invasion at the time of RP. Clinical and pathologic variables as well as biochemical outcome data were compared across the groups using rank‐sum, chi‐square, and log‐rank tests. Multivariate Cox proportional hazards analysis was used to determine the significant predictors of time to PSA failure among men with SV invasion.RESULTSMen with SV invasion had significantly higher PSA values, higher clinical stage, higher grade tumors, and were more likely to have concomitant extracapsular extension or a positive surgical margin. The 5‐year PSA progression–free rates for men who had SV invasion was 36%, compared with 70% among men who had no SV invasion. Among men who had SV invasion, using multivariate analysis, only age (P = 0.023), pathologic Gleason score (P = 0.041), and surgical margin status (P = 0.019) were found to be independent predictors of PSA failure. By combining significant prognostic variables, the authors identified a subset of men with SV invasion, low‐grade tumors (Gleason score 2–6), and negative surgical margins who had a 5‐year PSA progression–free rate of 69%. Men with SV invasion, Gleason scores 2–6 tumors, negative surgical margins, and age ≥ 60 years (n = 11; 8%) had a 5‐year PSA progression–free rate of 100%.CONCLUSIONSAlthough the majority of men with SV invasion have high‐grade disease and a short time to biochemical failure, the authors identified a subset of men with low‐grade disease, negative surgical margins, and older age who, despite SV invasion, had an extremely favorable clinical course. Thus, SV invasion does not uniformly suggest an unfavorable prognosis. prognosis. Cancer 2004. © 2004 American Cancer Society.
Biochemical failure after radical prostatectomy in men with pathologic organ‐confined disease: pT2a versus pT2b
Authors: Freedland Stephen J. , Partin Alan W. , Epstein Jonathan I. , Walsh Patrick C. 
Published: March 2004

AbstractBACKGROUNDThe 1997 TNM staging system for prostate carcinoma defines a pT2a disease as a tumor histologically involving one lobe of the prostate and pT2b disease as a tumor histologically involving both prostatic lobes. Whether this distinction provides prognostic significance is unclear. The authors evaluated biochemical outcomes between men with pT2aN0 and pT2bN0 disease.METHODSThe authors identified 1606 men with organ‐confined disease (pT2N0) who were treated with radical prostatectomy between 1982 and 2003 by one surgeon. Clinical characteristics were compared between men with pT2a and pT2b tumors using rank‐sum analysis, and prostate‐specific antigen (PSA) recurrence data were compared using log‐rank analysis. The significant independent predictors of PSA recurrence were determined using a multivariate Cox proportional hazards model.RESULTSThere were no significant differences between men with pT2a and pT2b tumors at the time of surgery in terms of clinicopathologic characteristics (biopsy and pathologic Gleason score, serum PSA level, clinical stage, and age). Log‐rank analysis revealed no significant differences in time to PSA recurrence between men with pT2a and pT2b tumors (P = 0.755). The 10‐year PSA progression‐free survival rate was 95% (confidence interval [CI], 92–97%) for men with pT2a tumors and 93% (CI, 90–95%) for men with pT2b tumors. Multivariate analysis showed that the significant predictors of PSA recurrence included serum PSA level, biopsy and pathologic Gleason score, and clinical stage. In the current cohort of men with organ‐confined disease, pathologic stage (pT2a vs. pT2b) was not a significant predictor of PSA recurrence on multivariate analysis.CONCLUSIONSThere was no difference in PSA recurrence rates between men with pT2aN0 versus pT2bN0 tumors. In men with organ‐confined disease, radical prostatectomy provided excellent 10‐year PSA progression‐free survival regardless of tumor burden (pT2a vs. pT2b). Consideration should be given to modifying the TNM staging system to eliminate substratification of pT2 tumors. Cancer 2004. © 2004 American Cancer Society.
Dysplasia in Barrett esophagus
Authors: Lao Christopher D. , Simmons Melanie , Syngal Sapna , Bresalier Robert S. , Fortlage Laurie , Normolle Daniel , Griffith Kent A. , Appelman Henry D. , Brenner Dean E. 
Published: March 2004

AbstractBACKGROUNDDysplasia in Barrett esophagus is a premalignant condition that is associated with an increased risk of developing esophageal adenocarcinoma. Unfortunately, clinical investigation aimed at prevention of progression to malignant disease has been hampered by the variable prevalence of dysplasia reported in the literature. The objective of the current study was to more accurately determine the prevalence of dysplasia among individuals with Barrett esophagus who would be available for enrollment in a chemoprevention trial.METHODSThe pathology archives of 3 institutions were reviewed over a 5‐year period for all reports of diagnoses of Barrett esophagus. Surgical cases, malignancies, and duplicate or referral cases were excluded from the analysis.RESULTSA total of 790 cases of Barrett esophagus were identified. Of these, 37 (4.7%) were cases of low‐grade dysplasia (LGD), and 20 (2.5%) were cases of high‐grade dysplasia. The University of Michigan Medical Center (Ann Arbor, MI) diagnosed 18 cases of LGD, Henry Ford Hospital (Detroit, MI) diagnosed 15 cases of LGD, and Brigham and Women's Hospital (Boston, MA) diagnosed 4 cases of LGD in patients with Barrett esophagus over the 5‐year study period.CONCLUSIONSThe confirmed low prevalence of cases of LGD will affect the design of future clinical trials of chemopreventive interventions for Barrett esophagus. Cancer 2004. © 2004 American Cancer Society.
ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas
Authors: Streiff Michael B. , Segal Jodi , Grossman Stuart A. , Kickler Thomas S. , Weir Edward G. 
Published: March 2004

AbstractBACKGROUNDVenous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with malignant gliomas. To investigate the pathogenesis of VTE and facilitate targeted prophylaxis strategies, the authors aimed to characterize VTE risk factors in these patients.METHODSThe authors conducted a retrospective chart review of 130 adult patients with glioma who received their primary therapy at the Johns Hopkins Hospital (Baltimore, MD) between 1991 and 2001. Symptomatic VTE was confirmed by objective radiologic testing. The association between clinical and laboratory characteristics and VTE was assessed using parametric and nonparametric statistical tests and survival analysis.RESULTSVTE developed in 28 patients (21.5%) at a median of 4.8 months after diagnosis (interquartile range, 2.1–13.2). Patients with tumors > 5 cm were more likely to develop VTE than patients with smaller tumors (hazard ratio = 2.2; P = 0.04). For every year increase in age, the hazard ratios for thrombosis increased by 3% (P = 0.011). When stratified by ABO blood group, the hazard ratios for thrombosis were 2.7 and 9.4 for patients with blood groups A (P = 0.045) and AB (P < 0.0001), respectively, compared with patients with blood group O. No association was observed between VTE and the other patient characteristics analyzed.CONCLUSIONSPatient age, tumor size, and particularly ABO blood group are risk factors for VTE among patients with malignant gliomas. These findings may facilitate the development of a thrombosis risk score that will allow physicians to individualize VTE prophylaxis regimens. Cancer 2004. © 2004 American Cancer Society.
New systemic frontline treatment for metastatic colorectal carcinoma
Authors: Braun Ada H. , Achterrath Wolf , Wilke Hansjochen , Vanhoefer Udo , Harstrick Andreas , Preusser Peter 
Published: March 2004

AbstractOptions for first‐line chemotherapy in patients with metastatic colorectal carcinoma have broadened considerably with the introduction of irinotecan and oxaliplatin. Furthermore, the oral fluoropyrimidine capecitabine has demonstrated efficacy in Phase III trials and recently was approved for first‐line treatment in Europe and the United States. Capecitabine yielded similar median times to disease progression and median survival rates compared with bolus 5‐fluorouracil (5‐FU)/leucovorin (LV) (Mayo Clinic/North Central Cancer Treatment Group regimen), with superior and similar response rates, respectively. However, its role as a first‐line, single‐agent substitute for intermittent infusional 5‐FU/LV remains to be defined. The addition of irinotecan or oxaliplatin to 5‐FU/LV resulted in improved response rates and progression‐free survival in large, randomized trials; moreover, irinotecan‐containing regimens resulted in improved overall survival. Prevalent regimens of irinotecan/5‐FU/LV and oxaliplatin/5‐FU/LV have been compared in two randomized Phase III trials. One study demonstrated the statistical superiority of oxaliplatin/infusional 5‐FU/LV over irinotecan/bolus 5‐FU/LV in terms of response, time to disease progression, and median survival; however, those advantages may have been attributable to infusional administration or to major differences in second‐line therapy. A randomized Phase III study comparing irinotecan and oxaliplatin in combination with the same infusional 5‐FU/LV regimens and crossover in case of disease progression showed equivalent efficacy for both schedules in the first‐line setting, but the irinotecan combination proved beneficial in terms of safety. New molecular targeted agents, such as angiogenesis‐modulating compounds (e.g., bevacizumab) and epidermal growth factor receptor inhibitors (e.g., cetuximab), are under clinical investigation. This review updates current systemic frontline treatments and future perspectives for patients with advanced colorectal carcinoma. Cancer 2004. © 2004 American Cancer Society.
Laparoscopic fluorescence detection of ovarian carcinoma metastases using 5‐aminolevulinic acid‐induced protoporphyrin IX
Authors: Löning Martin , Diddens Heyke , Küpker Wolfgang , Diedrich Klaus , Hüttmann Gereon 
Published: March 2004

AbstractBACKGROUNDThe aim of the current clinical study was to evaluate the in vivo fluorescence detection of ovarian carcinoma metastases in a second‐look laparoscopic procedure after intraperitoneally applied 5‐aminolevulinic acid (ALA).METHODSFive hours before laparoscopic surgery, ALA was applied intraperitoneally via short infusion in a concentration of 30 mg/kg bodyweight in a sterile, 1% solution. Application of ALA resulted in the endogenous production of the fluorescent photosensitizer, protoporphyrin IX (PP IX). The Combilight PDD 5133 system served as a light source, permitting the switch from white light mode to blue light mode to excite the PP IX accumulated in the ovarian tissue specimens. By means of blue light illumination, intraperitoneally located red fluorescent lesions, which were suspected to be metastases, underwent a biopsy. In addition, several biopsy specimens were taken from nonfluorescent areas of the peritoneal cavity.RESULTSIn 13 of 29 patients, ovarian carcinoma was confirmed histologically or cytologically. In 12 of these patients, metastases were visible by red fluorescence. In total, 123 biopsies were performed. Comparison of histologic assessment of the biopsy specimens with the fluorescence detection showed that strong red fluorescence had a sensitivity of 92% for detecting tumor tissue on specimens. In only 2% of all biopsy specimens was endometriosis observed in benign tissue specimens using fluorescence. In four of 13 patients with ovarian carcinoma, lesions were detected under fluorescence, which were not observed under white light illumination.CONCLUSIONSLaparoscopic fluorescence detection of endogenous PP IX after intraperitoneal application of ALA may provide a higher sensitivity of finding peritoneal metastases of epithelian ovarian carcinoma compared with conventional laparoscopy. Direct visualization of in vivo fluorescence after ALA application may improve the early detection of intraperitoneal ovarian carcinoma micrometastases. The high tissue selectivity of PP IX accumulation in tumor tissue specimens also offers the opportunity for therapeutic approaches using photodynamic therapy in the future. Cancer 2004. © 2004 American Cancer Society.
Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma
Authors: Chang Hao , Iizasa Toshihiko , Shibuya Kiyoshi , Iyoda Akira , Suzuki Makoto , Moriya Yasumitsu , Liu Tian‐Ling , Hiwasa Takaki , Hiroshima Kenzo , Fujisawa Takehiko 
Published: March 2004

AbstractBACKGROUNDAngiogenesis plays a crucial role in tumor growth and metastasis. Recently, some studies have focused on the angiogenesis inhibitor endostatin. However, the biologic role of the precursor of endostatin, collagen XVIII, in human malignancy is unknown. The purpose of the current study was to evaluate whether the expression of collagen XVIII has additional prognostic value for survival in patients with nonsmall cell lung carcinoma (NSCLC).METHODSThe authors investigated the expression of collagen XVIII in 221 patients using immunohistochemical methods. To confirm the specificity of the collagen XVIII polyclonal antibody used in the current study and to test the expression of collagen XVIII in human lung carcinoma, Western blot analysis was performed on a panel of human lung carcinoma cell lines.RESULTSCollagen XVIII expression was detected in 162 of 221 patients with NSCLC (73%), primarily in the tumor cell cytoplasm. Low collagen XVIII expression levels were found in 75 tumor specimens, while high collagen XVIII expression levels were noted in 87 tumor specimens. The prevalence of positive collagen XVIII expression was greater in T2–4 tumors than in T1 tumors (P = 0.0235). The prognosis for patients with strongly collagen XVIII–positive NSCLC was significantly worse than the prognosis for patients with collagen XVIII–positive or collagen XVIII–negative NSCLC (P = 0.0010). Multivariate analysis indicated that T status, lymph node status, and the overexpression of collagen XVIII were independent prognostic factors.CONCLUSIONSThe results of the current study indicated that the overexpression of collagen XVIII was associated with NSCLC progression and poor outcome. Thus, collagen XVIII expression may serve as a useful prognostic marker in patients with NSCLC. Cancer 2004. © 2004 American Cancer Society.